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Abstract 
Hyperlipoproteinemia represents a constellation of clinical syndromes that frequently 
includes hypertriglyceridemia. Because of the degree of elevation in the triglyceride 
levels frequently seen in these syndromes, they are associated with complications not 
generally observed among those patients with essential hypertriglyceridemia, including 
as in this case report, recurrent pancreatitis. Here, we present a case of a patient with 
hyperlipoproteinemia who developed acute worsening of his hypertriglyceridemia and 
onset of acute panceatitis that became recurrent following elective splenectomy for 
suspected lymphoma. In particular, we discuss the dietary management of 
hypertriglyceridemia which significantly reduced the number of episodes of acute 
pancreatitis in this patient. 
 
Introduction 
The hyperlipoproteinemias are a collection of hereditary lipid disorders characterized 
by severely elevated serum lipid levels [1]. The particular pattern of lipid elevation 
(primarily triglycerides, or primarily cholesterol, or a combined picture) is determined by 
the particular inherited defect. For example, lipoprotein lipase (LPL) deficiency impairs 
the conversion of triglyceride-rich particles into cholesterol moieties such as 
intermediate-density lipoprotein (IDL) and low-density lipoprotein (LDL). LPL defects 
are thus primarily associated with hypertriglyceridemia, and in particular, 
chylomicronemia [1]. Other metabolic defects lead to other patterns of lipid elevation. 
An uncommon, autosomal recessive deficiency in apolipoprotein CII results in 
impaired activity of LPL on chylomicrons and very low-density lipoprotein (VLDL). 
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Apolipoprotein CII is found on both chylomicrons and VLDL particles; this deficiency 
impairs the activity of LPL on these particles, preventing their conversion to IDL and 
LDL. As would be expected, this syndrome results in severe accumulation of the 
triglyceride-rich particles that can be very difficult to control even with aggressive medical 
treatment and lifestyle changes [1]. 
What is not well defined in the literature are adaptive responses the body undertakes in 
response to these extreme changes in the lipid profile. Although numerous consequences 
including accelerated atherosclerosis and foam cell formation, fatty liver, and 
splenomegaly have been described, they have generally been considered sequelae of the 
disease. Here, we present a case of hypertriglyceridemia with elevated chylomicrons and 
VLDL associated with massive splenomegaly that was acutely exacerbated by elective 
splenectomy. 
Case Report 
In January 1996, a 45-year-old white, male construction worker presented to his primary care 
physician for a routine annual physical examination. His medical and surgical history was significant for 
a cholecystectomy in 1982 due to cholecystitis that was believed to be secondary to clofibrate, which he 
was taking for hypercholesterolemia. He also had had an episode of acute pancreatitis in 1990 that was 
attributed to three weeks of heavy alcohol intake consisting of approximately six beers a day. He 
subsequently abstained from any further alcohol intake or tobacco use. The medical history was 
otherwise unremarkable. He took no other medications or herbal supplements. There was no family 
history of diabetes; his father was in good health and his mother had died of colon cancer. A review of 
systems was non-contributory, and the physical exam was unremarkable. Routine blood tests revealed 
an elevated blood glucose level consistent with diabetes, cholesterol of 271 mg/dl, and a triglyceride level 
of 2,527 mg/dl. He was diagnosed with adult onset diabetes and hyperlipidemia and was prescribed 
lifestyle modifications and gemfibrozil 600 mg twice a day. In February 1996, after failing to control the 
elevated blood glucose with dietary changes, he was prescribed glipizide 5 mg once a day and nizatidine 
150 mg twice a day. He subsequently began experiencing hypoglycemic episodes. Daily monitoring 
confirmed that blood glucose levels were consistently below 100 mg/dl. As a result, the hypoglycemic 
agents were discontinued. Interestingly, once off hypoglycemic medications, he maintained stable 
fasting blood sugars that were subsequently paralleled with hemoglobin A1c values between 3.7 and 5.4. 
The cause of his history of hyperglycemia was never specifically identified. 
On the other hand, control of the hyperlipidemia proved more elusive. Over the following six years, 
from January 1996 to May 2002, he was prescribed a variety of lipid-lowering agents but with limited 
degrees of success. In January 1996, he was first prescribed gemfibrozil; cholestyramine was added seven 
months later due to persistently elevated triglycerides. (The cholestyramine had to be replaced with 
colestipol after one month due to constipation.) In April 1998, an HMG-CoA reductase inhibitor was 
added but substituted with another after one month due to myalgias. This resulted in a reduction of 
total cholesterol to less than 200 mg/dl, but the triglycerides remained elevated at 2,845 mg/dl. Nine 
months later gemfibrozil was discontinued due to leukopenia. 
In June 1999, he was found to be hypothyroid and was started on thyroid replacement. Although the 
hypothyroidism was thought to contribute to his hyperlipidemia, both cholesterol and triglyceride 
progressively increased despite achieving a euthyroid state. By December 1999, cholesterol and 
triglyceride levels had increased to 344 and 4,044 mg/dl, respectively. He was then started on 
fenofibrate, and niacin was later added. 
From November 2000 until his hospitalization in May 2002 he remained on maximal doses of an 
HMG-CoA reductase inhibitor, fenofibrate, and niacin. During this period total cholesterol and 
triglyceride levels remained elevated and fluctuated between 335 and 450 mg/dl, and between 4,390 and 
5,380 mg/dl, respectively. 
In May 2002, he was hospitalized for abdominal pain with an enlarged spleen on exam. Abdominal 
ultrasound and CT scan confirmed massive splenomegaly, whereas liver size was normal; there was no 
comment regarding the presence or absence of a portal or splenic vein thrombosis. A complete 
evaluation, which included complete blood count with peripheral smear, bone marrow aspiration and 
biopsy, and rheumatologic serologies, revealed no obvious cause for the splenomegaly. Splenectomy was 
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performed for persistent abdominal pain and suspicion of primary splenic lymphoma. However, the 
pathology showed only lipid-laden macrophages and no evidence of a malignant process. With 
improvement in his symptoms, he was discharged to outpatient follow-up for ongoing care including 
pneumococcal vaccination. 
Four weeks after splenectomy, he presented to his physician’s office complaining of left upper 
quadrant and severe upper abdominal pain with nausea. On physical examination, he was found to be 
normotensive and afebrile with a soft abdomen and some guarding but no rebound tenderness. The 
work-up included laboratories that revealed elevated amylase, lipase, and triglycerides; imaging to rule 
out a postoperative complications and thrombosis was not done at this time. This was the first of 
numerous episodes of pancreatitis due to hypertriglyceridemia that continued to plague him. 
Interestingly, following the splenectomy, both total cholesterol and triglyceride levels showed a dramatic 
rise; by April 2003, they had reached 1,020 and 11,290 mg/dl, respectively, at which time he was referred 
to UCLA (see table 1). Of note, the triglyceride-rich VLDL represented 98% of the total cholesterol on 
fractionation, that is, the patient had markedly elevated VLDL associated with low LDL and HDL. 
However, given the degree of elevation of the total triglyceride level, the severe hypertriglyceridemia 
measured was associated with, but not explained by, the elevated VLDL. This clinical picture suggested a 
hypertriglyceridemia syndrome characterized by elevated VLDL and severe chylomicronemia. 
Discussion 
Plasma triglycerides originate from either dietary sources or de novo hepatic synthesis. 
In the intestine, dietary triglycerides are packaged into chylomicrons. In the liver, 
triglyceride accumulation stimulates VLDL production. After a 12-hour fast, moderate 
hypertriglyceridemia (up to approximately 600 mg/dl) may result from increased hepatic 
synthesis. When fasting triglyceride values exceed 600–800 mg/dl there is saturation of 
the triglyceride clearance process mediated by LPL. As a consequence of the saturation of 
the LPL system, chylomicron clearance is diminished, resulting in the accumulation of 
both chylomicrons and VLDL. This accumulation often leads to triglyceride levels of 
1,000 mg/dl and higher. The presence of chylomicrons in association with triglyceride 
levels above 1,000 mg/dl is referred to as chylomicronemia syndrome [2]. If the LPL 
system is impaired, it may contribute to diminished clearance and chylomicronemia as 
well. This occurs in a variety of situations caused by acquired and/or genetic 
abnormalities of LPL or its lipoprotein receptor [1]. 
Interestingly, splenomegaly due to the accumulation of lipid-laden histiocytes is not 
associated with hypertriglyceridemia except in patients with chronic severe 
chylomicronemia. It is, however, found in other disorders in the notable absence of 
hypertriglyceridemia. These include cholesterol ester storage disease and lysosomal 
storage diseases such as Niemann-Pick variant, Gaucher disease, lecithin-cholesterol 
acyltransferase deficiency, and Tangier disease [3]. The clinical manifestations associated 
with these syndromes include skeletal, ophthalmologic, hematologic, neurologic, cardiac, 
and hepatic abnormalities. The case presented here did not have any of the 
aforementioned clinical abnormalities, suggesting that hypertriglyceridemia was most 
likely the cause of the splenomegaly. 
Whether or not hypertriglyceridemia is independently associated with an increased 
risk of coronary artery disease is controversial [4]. For example, with rare exceptions, 
patients with chylomicronemia due to mutations in the LPL gene (type I 
lipoproteinemias) do not have an increased risk of cardiovascular disease despite total 
cholesterol and triglyceride levels as high as 1,000 and 10,000 mg/dl, respectively [1]. On 
the other hand, patients with elevated levels of IDL and LDL or remnant dyslipidemia due 
to apoE mutations (types IIb and III lipoproteinemia, respectively) that are also 
characterized by high total cholesterol and triglyceride levels, have an increased risk of 
coronary artery disease [5, 6]. The difference seems to be due to the lipoproteins involved. 
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In chylomicronemia, the chylomicrons are thought to be so large that their entry into the 
subendothelial space is retarded so that arterial wall macrophages are not exposed to these 
large particles [7]. On the other hand, in patients with dyslipidemia due to elevated levels 
of LDL, IDL, and possibly VLDL, these smaller lipoproteins may have greater access to 
the subendothelial space where they can be ingested by macrophages that transform into 
atherogenic foam cells [7, 8]. Given the low LDL and HDL, and the markedly elevated 
cholesterol and triglycerides (manifested as chylomicrons and VLDL), the patient 
presented here probably has type V lipoproteinemia most consistent with either LPL 
deficiency or a deficiency in apolipoprotein CII. Of note, types I and V have been 
associated with the same genetic defects and likely simply represent a variation in clinical 
presentation (see table 2). 
Severe hypertriglyceridemia associated with chylomicronemia is a recognized risk 
factor for developing pancreatitis, but it only accounts for approximately 1.3–3.8% of all 
acute cases [9]. Typically, pancreatitis does not occur unless levels are greater than 1,000 
mg/dl [10]. Although the mechanism is unknown, some have suggested that the liberation 
of free fatty acids by pancreatic lipase results in toxic injury to the capillary endothelium 
and pancreatic acinar cells [10, 11]. In isolated perfused pancreatic preparations, for 
example, the addition of free fatty acids produced edema and hemorrhage in the pancreas 
[11]. There is some evidence to suggest that liberation of certain free fatty acids from 
triglyceride molecules may predispose to more severe episodes of pancreatitis. For 
example, increased levels of polyunsaturated free fatty acids and in particular, linoleic and 
arachidonic acids, were retrospectively associated with increased rates of complications 
from acute pancreatitis [12]. Since the choice of surgical or medical approach to the 
management of acute pancreatitis may depend on the presence or likelihood of 
developing complications [13], early evaluation of liberated free fatty acids, in patients 
with severe hypertriglyceridemia, may be of some benefit. 
Even though hypertriglyceridemia is a risk factor for pancreatitis and dramatic 
triglyceride elevations have been reported after splenectomy, to our knowledge there is 
only one case report of pancreatitis due to hypertriglyceridemia following a splenectomy. 
In the letter to the editor, Schmidt et al. described the development of 
hypertriglyceridemia and a subsequent episode of pancreatitis in a patient following a 
traumatic splenectomy [14]. The triglyceride level was noted to rise markedly after the 
splenectomy and was recorded to be as high as 4,500 mg/dl. As in the case reported by 
Schmidt et al., our case also demonstrates worsening hypertriglyceridemia and the 
development of pancreatitis following splenectomy. Furthermore, the presence of lipid-
laden macrophages in the splenic tissue following splenectomy seen on histopathology 
strongly suggested that the spleen served an important role as a site of chylomicron 
triglyceride clearance. Presumably, abolition of this clearance process resulted in a 
marked rise in serum triglycerides that led to recurrent episodes of pancreatitis. 
Once the acute pancreatitis had resolved, control of the hypertriglyceridemia remained 
the goal of therapy. The typical management of hypertriglyceridemia consists of 
avoidance of alcohol, weight reduction, discontinuation of offending drugs, and control 
of diabetes mellitus and hypothyroidism [15]. It is important to note that fat restriction 
plays a pivotal role in management but must be performed in conjunction with exercise 
and weight reduction. Control of dietary fat intake, saturated and unsaturated, is the 
cornerstone of nutritional intervention. Dietary fat should be reduced to no more than 10 
to 15% of total caloric consumption. If it does not adequately reduce triglycerides and 
prevent pancreatitis, then consideration should be given to using medium chain 
triglycerides, which bypass chylomicron formation and are taken up from the portal vein 
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by the liver. In addition, supplementation with fish oil can decrease endogenous 
production of triglyceride-rich lipoproteins. It has been shown that daily intake of 3–4 g 
of fish oil, consisting of equal amounts of eicosapentaenoic and docosahexaenoic acids, 
will decrease plasma triglyceride levels by 30–50% in patients with hypertriglyderidemia 
[16, 17]. Drug treatment with a fibric acid derivative (gemfibrozil, fenofibrate or 
clofibrate) or niacin may help to decrease triglyceride levels by limiting hepatic 
production of VLDL. However, niacin use may be limited by its known side effects 
(flushing, pruritus, hepatotoxicity, glucose intolerance, hyperuricemia and gastric upset). 
HMG-CoA reductase inhibitors are not primarily used in the management of 
hypertriglyceridemia. 
In this patient, treatment consisted of adhering to a strict diet limited to less than 20 g 
of fat per day in combination with daily doses of fenofibrate (160 mg), atorvastatin (40 
mg), fish oil (6 g), and niacin (1,000 mg). Following this strict dietary and medical 
regimen, the patient’s cholesterol and triglyceride were reduced to 630 and 3,940 mg/dl, 
respectively and recurrent episodes of acute pancreatits resolved. 
Summary 
We believe that our patient developed worsening hypercholesterolemia and 
hypertriglyceridemia as a result of his splenectomy. It appears that the spleen served as a 
site of storage for lipids. This is supported by the pathological changes in the spleen and 
the concomitant rise in serum lipids following its removal. As a result, this sudden rise in 
serum triglycerides was the cause of the recurrent episodes of pancreatitis. 
The case presented here illustrates the challenges encountered by physicians when 
managing and treating patients with lipid disorders. Physicians need to be familiar with 
the different types of lipid abnormalities, the clinical manifestations and laboratory 
findings, and the different treatments available, whether there are dietary modifications, 
the use of pharmaceutical agents, or a combination of the two. Furthermore, it is 
necessary that physicians be aware of the complications associated with lipid disorders, 
including those associated with their treatment, such as side effects of the medication, or, 
as in the case here, the development of pancreatitis following splenectomy. 
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Table 1. Cholesterol and triglyceride levels from 11/2000 through 3/2004. Splenectomy was performed 
in May 2002 (*) after which lipids proceeded to rise to the highest levels recorded 
 11/00 5/01 12/01 5/02* 6/02 7/02 8/02 11/02 1/03 2/03 4/03 3/04 
Cholesterol, mg/dl 0.440 0.335 0.350 0.218 211 0.970 00.850 0.530 0.700 0.840 01,020 0.630
Triglyceride, mg/dl 4,760 4,800 5,380 1,300 626 6,940 10,410 3,030 8,780 8,190 11,290 3,940
 
 
Table 2. Phenotypes and classification of hyperlipidemic syndromes 
Elevated moiety Hyperlipidemia 
classification 
Common pathogenic defects Disease name Findings and symptoms 
Chylomicrons I 
  
Lipoprotein lipase deficiency 
Apolipoprotein CII deficiency 
Familial LPL deficiency 
Familial CII deficiency 
Pancreatitis, eruptive 
xanthomas (trunk and 
extremities), and 
hepatosplenomegaly 
V Chylomicrons 
and VLDL  
Lipoprotein lipase deficiency 
Apolipoprotein CII deficiency 
Familial LPL deficiency 
Familial CII deficiency 
Pancreatitis, eruptive 
xanthomas (trunk and 
extremities), and 
hepatosplenomegaly 
VLDL IV Unknown Familial hypertriglyceridemia As above; may have increased 
vascular risk 
(VLDL), IDL III Apolipoprotein E mutation 
(E2/E2)* 
Familial dysbetalipoproteinemia Vascular disease, tuberous 
xanthomas 
VLDL, LDL IIB Multiple Familial combined hyperlipidemia Vascular disease 
LDL IIA 
  
Multiple 
Decreased LDL receptors 
Familial combined hyperlipidemia 
Familial hypercholesterolemia 
Vascular disease 
Vascular disease, tuberous and 
tendinous xanthomas 
*E2 is the defective allele of apolipoprotein E, which cannot bind its receptor. 
Adapted from [1]. 
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